Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Dulaglutide
CAS: 923950-08-7
El GLP-1 más prescrito con datos cardiovasculares
Dulaglutide is a research peptide in the glp-1 / weight management category. Dulaglutide is a GLP-1 receptor agonist that consists of a modified GLP-1 analog fused to a human IgG4 Fc domain. MiPeptidos offers Dulaglutide in 2 sizes with 99.1% verified purity and full analytical documentation.
- Proven heart protection
- 100M+ prescriptions worldwide
- Once-weekly convenience
- Kidney health support
Research suggests moderate appetite reduction begins within the first 1-2 weeks. Dulaglutide is the most established GLP-1 with over 100 million prescriptions filled worldwide, so its effects are well-documented. By weeks 4-8, studies report modest but steady weight loss of about 5-6% of body weight. The major advantage is cardiovascular protection — the REWIND trial showed a 12% reduction in heart events. Users who prioritize proven safety data and heart health benefits over maximum weight loss often prefer dulaglutide.
$50.29/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Proven Weekly GLP-1.
16-week protocol backed by AWARD trials, REWIND cardiovascular data, and 100M+ prescriptions globally
Dulaglutide (Trulicity) is an established once-weekly GLP-1 receptor agonist developed by Eli Lilly, approved in 2014 for type 2 diabetes. It uses an Fc-fusion protein design linking a GLP-1 analog to a modified IgG4 Fc fragment, enabling once-weekly dosing with a half-life of approximately 5 days.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Hertzel Gerstein
Professor of Medicine, McMaster University; Director, Diabetes Trials Unit
Lead investigator of the REWIND trial — the most broadly inclusive GLP-1 cardiovascular outcomes trial. Over 500 publications in diabetes and cardiovascular research.
REWIND demonstrated that dulaglutide reduces cardiovascular events in a broad type 2 diabetes population, not just those at extremely high risk. This has important implications for primary prevention.
The cardiovascular benefit was observed with dulaglutide 1.5mg weekly. For CV risk reduction, the lower maintenance dose may be sufficient. Higher doses (3.0mg, 4.5mg) are for additional weight loss.
Fuente: REWIND trial (Lancet, 2019, PMID: 31189511); McMaster University research
Dr. Vivian Fonseca
Professor of Medicine, Tulane University School of Medicine
Past President of Medicine & Science at the American Diabetes Association. Leading endocrinologist with 40+ years of clinical research in diabetes therapeutics.
Dulaglutide has the broadest prescribing experience of any GLP-1 receptor agonist. The safety database from over 100 million prescriptions provides clinicians with unmatched confidence.
Start at 0.75mg weekly and escalate to 1.5mg after 4 weeks. The 3.0mg and 4.5mg doses provide additional weight loss but were developed later. For diabetes focus, 1.5mg is often sufficient.
Fuente: ADA Scientific Sessions; Diabetes Care editorial reviews
Dr. Katherine Tuttle
Professor of Medicine, University of Washington; Executive Director, Providence Research Network
Nephrologist and leading expert on diabetic kidney disease. REWIND renal substudy investigator.
Dulaglutide showed a 15% reduction in the composite renal outcome in REWIND. The renoprotective effects of GLP-1 agonists may be as important as their cardiovascular benefits.
For patients with diabetic kidney disease, dulaglutide offers both cardiovascular and renal protection. Monitor eGFR and albumin-creatinine ratio during treatment.
Fuente: REWIND renal substudy (Lancet, 2019); ASN presentations
Dr. John Buse
Director, Diabetes Center, University of North Carolina
Past President, ADA. Professor of Medicine and Chief of Endocrinology at UNC. AWARD program investigator.
Dulaglutide established that once-weekly GLP-1 receptor agonism is effective and well-tolerated. The AWARD program provided 7+ trials that mapped the efficacy landscape before semaglutide arrived.
The AWARD trials showed dulaglutide 1.5mg reduced HbA1c by 1.1-1.6% across different comparators. For patients already well-controlled on dulaglutide, consider whether switching to newer agents is necessary.
Fuente: AWARD program publications; ADA treatment guideline contributions
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Starting dose for GI tolerability. This dose alone provides meaningful HbA1c reduction. GI side effects are milder at this dose than with more potent GLP-1 agonists.
Standard maintenance dose for diabetes. This was the dose used in REWIND for cardiovascular benefit. Many protocols stabilize here for glycemic and CV purposes.
Higher doses (approved 2020) for additional weight loss. Escalate to 3.0mg for 4 weeks, then 4.5mg if tolerated. The 4.5mg dose provides ~5-6% mean weight loss — modest but meaningful for cardiometabolic improvement.
Research-grade lyophilized dulaglutide: reconstitute 5mg vial with 1mL bacteriostatic water = 5mg/mL. For 0.75mg = 0.15mL (15 units). For 1.5mg = 0.3mL (30 units). For 4.5mg = 0.9mL (90 units). Fc-fusion protein — do not vortex.
Dulaglutide is designed for continuous long-term use — not cycled. REWIND followed patients for 5.4 years with sustained benefit. Weight regain and glycemic deterioration occur upon discontinuation.
Lyophilized: store at -20°C. Reconstituted: refrigerate at 2-8°C, use within 30 days. Branded Trulicity pens: refrigerate, or room temperature up to 14 days. Protect from light.
Subcutaneous injection once weekly on the same day. Rotate injection sites. Can be administered at any time, with or without meals. If a dose is missed, administer within 3 days; if more than 3 days late, skip and resume regular schedule.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
GLP-1 Receptor Activation & GI Adaptation
- GLP-1 receptor engagement via Fc-fusion sustained delivery
- Glucose-dependent insulin secretion enhanced from first dose
- Mild appetite suppression as hypothalamic pathways engage
- GI adaptation — nausea is less common than with semaglutide (~15-20%)
- Typical weight loss: 0.5-1.5% of body weight
Base de investigación: AWARD-1 (Wysham et al., 2014, Lancet, PMID: 24931715)
Therapeutic Dosing & Glycemic Improvement
- 1.5mg dose provides meaningful HbA1c reduction of 1.1-1.6%
- Fasting and postprandial glucose significantly improved
- Appetite modulation with modest but consistent food intake reduction
- GI tolerance typically established — side effects diminishing
- Typical weight loss: 2-4% of body weight
Base de investigación: AWARD program (AWARD-1 through AWARD-11); Trulicity prescribing information
Higher Dose Titration & Enhanced Weight Effects
- 3.0-4.5mg doses provide additional weight loss beyond glycemic doses
- At 4.5mg: approximately 5-6% mean weight loss at 36 weeks
- Cardiovascular risk markers improving: blood pressure, lipids, CRP
- Renal protection markers (eGFR stability, albumin reduction) emerging
- Weight loss continues to accumulate through week 36+
Base de investigación: AWARD-11 dose-escalation data; Trulicity 3.0mg/4.5mg approval data
Long-Term Cardiovascular & Renal Protection
- REWIND: 12% MACE reduction (HR 0.88) over 5.4 years with 1.5mg
- 15% reduction in composite renal outcome in REWIND renal substudy
- Sustained HbA1c and body weight benefits with continued treatment
- The most extensive long-term GLP-1 RA safety database (100M+ prescriptions)
- Ongoing therapy recommended for cardiorenal protection and metabolic maintenance
Base de investigación: REWIND (Gerstein et al., 2019, Lancet, PMID: 31189511); REWIND renal substudy
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
GLP-1 Receptor Agonism (Fc-Fusion Platform)
A modified GLP-1 analog fused to an IgG4 Fc fragment, providing sustained GLP-1 receptor activation with a ~5-day half-life for once-weekly dosing.
- 90% homology to native GLP-1 with DPP-IV resistance modifications
- IgG4 Fc fusion reduces renal clearance and extends half-life to ~5 days
- Activates GLP-1R for glucose-dependent insulin secretion (low hypoglycemia risk)
- Steady-state achieved by week 2-4 of weekly dosing
Trulicity prescribing information; Glaesner et al. (2010) Diabetes Metab Res Rev
Cardiovascular Protection
Reduces major adverse cardiovascular events through anti-inflammatory and metabolic mechanisms demonstrated in the broadest-population GLP-1 CVOT.
- REWIND: 12% MACE reduction over 5.4 years — the longest GLP-1 CVOT
- Uniquely included patients at lower CV risk — not just secondary prevention
- Reduces inflammatory markers, blood pressure, and atherogenic lipids
- HR 0.88 for MACE — consistent benefit across subgroups
REWIND (PMID: 31189511); Gerstein et al. (2019) Lancet
Renal Protection
Provides renal protection through reduced albuminuria and preserved eGFR, demonstrated in the REWIND renal substudy.
- 15% reduction in composite renal outcome (REWIND)
- 23% reduction in macroalbuminuria — a key marker of diabetic kidney disease
- eGFR decline attenuated compared to placebo
- GLP-1 receptors in kidney tubular cells may mediate direct renoprotective effects
REWIND renal substudy (PMID: 31189514); Gerstein et al. (2019) Lancet
Investigación Publicada
5 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, et al. — The Lancet (2019)
Hallazgo Clave: REWIND: Dulaglutide 1.5mg reduced MACE by 12% (HR 0.88, 95% CI 0.79-0.99) over 5.4 years in 9,901 T2D patients. Uniquely included lower-risk patients — broadening the applicable population.
AWARD-1: Dulaglutide versus exenatide and placebo in T2D
Wysham C, Blevins T, Arakaki R, et al. — The Lancet (2014)
Hallazgo Clave: Dulaglutide 1.5mg reduced HbA1c by 1.51% — superior to exenatide 10mcg twice daily. Weight loss of 1.3kg at 26 weeks. Established dulaglutide's place in the GLP-1 class.
Dulaglutide and renal outcomes in type 2 diabetes: REWIND renal substudy
Gerstein HC, Colhoun HM, Dagenais GR, et al. — The Lancet (2019)
Hallazgo Clave: REWIND renal: dulaglutide reduced the composite renal outcome by 15% (HR 0.85). Macroalbuminuria reduced by 23%. First GLP-1 RA to demonstrate renal protection in a dedicated substudy.
AWARD-11: Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg vs 1.5 mg in T2D
Frias JP, Bonora E, Nevarez Ruiz L, et al. — Diabetes Care (2021)
Hallazgo Clave: AWARD-11: Higher doses provided additional HbA1c reduction (up to -1.9% at 4.5mg) and weight loss (up to -5.0 kg at 4.5mg). Dose-response confirmed for both glycemic and weight endpoints.
Comparative effectiveness of GLP-1 receptor agonists: systematic review and network meta-analysis
Htike ZZ, Zaccardi F, Papamargaritis D, et al. — Diabetes, Obesity and Metabolism (2017)
Hallazgo Clave: Network meta-analysis: dulaglutide 1.5mg ranked among the top GLP-1 RAs for HbA1c reduction but produced modest weight loss. Semaglutide ranked first for weight reduction.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar Dulaglutide con estos péptidos para mecanismos complementarios.
Semaglutide achieves ~2.5x greater weight loss than dulaglutide. For patients who tolerate dulaglutide but need more weight loss, upgrading to semaglutide is a proven strategy.
NOTE: These are alternatives, not combined. Dulaglutide → semaglutide is a common clinical escalation pathway when weight loss is the primary goal beyond glycemic control.
BPC-157 provides GI mucosal protection during dulaglutide therapy, particularly for patients escalating to higher doses (3.0-4.5mg).
May support GI tolerance during dose escalation to higher weight-management doses, reducing discontinuation risk.
AOD-9604 may enhance dulaglutide's modest weight loss with direct fat metabolism stimulation for patients seeking greater body composition change.
May boost overall fat loss for patients who need cardiometabolic protection (dulaglutide) but want additional body composition improvement beyond what dulaglutide alone provides.
Ipamorelin provides clean GH secretion to help preserve lean mass during weight loss, without significant cortisol or prolactin effects.
A gentle lean-mass preservation approach that complements dulaglutide's more moderate weight loss profile.
Especificaciones
Cómo Funciona Dulaglutide
Dulaglutide is a GLP-1 receptor agonist that consists of a modified GLP-1 analog fused to a human IgG4 Fc domain. The Fc fusion dramatically extends the half-life by reducing renal clearance and engaging FcRn-mediated recycling. It stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, delays gastric emptying, and reduces appetite through central nervous system signaling.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
5mg | $120.00 | $1020.00 |
10mgMejor Valor | $200.00 | $1700.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved in research peptide form
Only branded Trulicity (0.75mg-4.5mg pens) is FDA-approved. Research-grade dulaglutide is not approved for human use. Trulicity is manufactured as a complex Fc-fusion protein requiring specific quality controls.
Thyroid C-cell tumors (Boxed Warning)
Dulaglutide causes thyroid C-cell tumors in rodents. CONTRAINDICATED with personal or family history of MTC or MEN 2.
Pancreatitis risk
Acute pancreatitis reported. Higher risk than placebo in clinical trials. Discontinue immediately if persistent severe abdominal pain occurs.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Up to 50% OffSemaglutide
Estudiado clínicamente para una reducción de peso constante — una vez por semana
Up to 60% OffTirzepatide
El agonista dual más estudiado para la reducción de peso
Up to 42% OffRetatrutide
Agonista de triple receptor estudiado para una actividad metabólica mejorada
Up to 38% OffLiraglutide
GLP-1 diario estudiado para la regulación constante del apetito